Company Description

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company.

It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.

Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury.

The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

The company was incorporated in 2012 and is headquartered in New York, New York.

Synaptogenix, Inc.

Country	United States
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Alan Tuchman

Contact Details

Address: 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States
Phone	973 242 0005
Website	synaptogen.com

Stock Details

Ticker Symbol	SNPX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001571934
CUSIP Number	87167T201
ISIN Number	US87167T2015
Employer ID	46-1585656
SIC Code	2834

Key Executives

Name	Position
Dr. Alan J. Tuchman M.D., MBA(FAAN)	Chief Executive Officer and Director
Dr. Daniel L. Alkon M.D.	President, Chief Scientific Officer and Director
Robert Weinstein	Chief Financial Officer, Executive Vice President, Treasurer and Secretary

Latest SEC Filings

Date	Type	Title
Dec 20, 2024	8-K	Current Report
Dec 6, 2024	8-K	Current Report
Nov 20, 2024	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 12, 2024	10-Q	Quarterly Report
Nov 7, 2024	DEF 14A	Other definitive proxy statements
Nov 5, 2024	ARS	Filing
Oct 28, 2024	PRE 14A	Other preliminary proxy statements
Oct 21, 2024	EFFECT	Notice of Effectiveness
Oct 16, 2024	UPLOAD	Filing
Oct 10, 2024	S-3	Registration statement under Securities Act of 1933

View All SEC Filings